Literatur
-
1
Aisen P S, Pasinetti G M.
Glucocorticoids
in Alzheimer"s disease. The story so far.
Drugs &
Aging.
1998;
12
1-6
-
2 American Psychiatric
Association .Diagnostic Criteria from the
DSM-IV. American Psychiatric Press, Washington,
DC 1994
-
3
American Psychiatric
Association .
Practice guideline for the treatment of patients with
Alzheimer"s disease and other dementias of late life.
Am J
Psychiatry.
1997;
154
(Suppl)
1-39
-
4
Ando Y, Suhr O, El-Salhy M.
Oxidative
stress and amyloidosis.
Histol
Histopathol.
1998;
13
845-850
-
5
Avery E E, Baker L D, Asthana S.
Potential
role of muscarinic agonists in Alzheimer"s disease.
Drugs &
Aging.
1997;
11
450-459
-
6
Birkhäuser M H, Strnad J, Kämpf C, Bahro M.
Estrogens
and Alzheimer’s disease.
Int J Geriatr
Psychiatry.
2000; ;
im
Druck
-
7
Cummings J L, Masterman D L.
Assessment
of treatment-associated changes in behavior and cholinergic therapy of
neuropsychiatric symptoms in Alzheimer"s disease.
J Clin
Psychiatry.
1998;
59
(Suppl)
23-30
-
8
Doody R S.
Clinical
profile of donepezil in the treatment of Alzheimer"s
disease.
Gerontology.
1999;
45
(Suppl.)
23-32
-
9
Farlow M R, Evans R M.
Pharmacologic
treatment of cognition in Alzheimer"s
dementia.
Neurology.
1998;
51
(Suppl.)
S36-S44
-
10 Feldman R S, Meyer J S, Quenzer L F. Principles
of Neuropsychopharmacology. Sinauer Associates Publishers,
Sunderland,
Massachusetts 1997
-
11
Felician O, Sandson T A.
The
neurobiology and pharmacotherapy of Alzheimer"s disease.
J
Neuropsychiatry Clin
Neurosci.
1999;
11
19-31
-
12
Flynn B L.
Pharmacologic
management of Alzheimer disease. Part I: Hormonal and emerging investigational
drug therapies.
Ann
Pharmacother.
1999;
33
178-187
-
13
Flynn B L, Ranno A E.
Pharmacologic
management of Alzheimer disease. Part II: antioxidants, antihypertensives, and
ergoloid derivatives.
Ann
Pharmacother.
1999;
33
188-197
-
14
Giacobini E.
Aging,
Alzheimer"s disease, and estrogen therapy.
Experimental
Gerontology.
1998;
33
865-869
-
15
Hendrie H C.
Epidemiology
of dementia and Alzheimer"s disease.
Am J Geriatr
Psychiatry.
1998;
6
S3-S18
-
16
Kumar V, Nalla U, Durai B, Jobe T.
Pharmacologic
management of Alzheimer"s disease.
Clinics in Geriatric
Medicine.
1998;
14
129-146
-
17
Lawrence A D, Sahakian B J.
The
cognitive psychopharmacology of Alzheimer"s disease: Focus on cholinergic
systems.
Neurochemical
Research.
1998;
23
787-794
-
18
Levy M L, Cummings J L, Kahn-Rose R.
Neuropsychiatric
symptoms and cholinergic therapy for Alzheimer"s
disease.
Gerontology.
1999;
45
(Suppl)
15-22
-
19
Lynch G, Granger R, Ambros-Ingerson J, Davis C M, Kessler M, Schehr R.
Evidence
that a positive modulator of AMPA-type glutamate receptors improves delayed
recall in aged humans.
Exp
Neurol.
1997;
145
89-92
-
20
Meneses A.
Physiological,
pathophysiological and therapeutic roles of 5-HT systems in learning and
memory.
Reviews in
Neurosciences.
1998;
9
275-289
-
21
Nordberg A, Svensson A -L.
Cholinesterase
inhibitors in the treatment of Alzheimer"s disease. A comparison of
tolerability and pharmacology.
Drug
Safety.
1998;
19
465-480
-
22
Oken B S, Storzbach D M, Kaye J A.
The
efficacy of Ginkgo biloba on cognitive function in Alzheimer
disease.
Arch
Neurol.
1998;
55
1409-1415
-
23
Pitchumoni S S, Doraiswamy P M.
Current
status of antioxidant therapy for Alzheimer"s disease.
J Am
Geriatr
Soc.
1998;
46
1566-1572
-
24
Poirier J, Sévigny P.
Apolipoprotein
E4, cholinergic integrity and the pharmacogenetics of Alzheimer"s
disease.
J Neural
Transm.
1998;
53
(Suppl)
199-207
-
25
Richards S S, Hendrie H C.
Diagnosis,
management, and treatment of Alzheimer disease.
Arch Intern
Med.
1999;
159
789-797
-
26
Rogers S L.
Perspectives
in the management of Alzheimer"s disease: Clinical profile of
donepezil.
Dementia Geriatr Cogn
Disord.
1998;
9
(
Suppl)
29-42
-
27
Rösler M, Retz W, Thome J, Riederer P.
Free
radicals in Alzheimer"s dementia: Currently available therapeutic
strategies.
J Neural
Transm.
1998;
54
(Suppl)
211-219
-
28
Shadlen M -F, Larson E B.
What"s
new in Alzheimer"s disease treatment? Reasons for optimism about future
pharmacologic options.
Postgraduate Medicine/Alzheimer"s
disease.
1999;
105
109-118
-
29
Sirviö J.
Strategies
that support declining cholinergic neurotransmission in Alzheimer’s
disease
patients.
Gerontology.
1999;
45
(Suppl)
3-14
-
30
Small G W, Rabins P V, Barry P P. et
al .
Diagnosis and treatment of Alzheimer disease and related
disorders. Consensus statement of the American Association for Geriatric
Psychiatry, the Alzheimer"s Association, and the American Geriatrics
Society.
JAMA.
1997;
278
1363-1371
-
31
Spencer C M, Noble S.
Rivastigmine.
A review of its use in Alzheimer"s disease.
Drugs &
Aging.
1998;
13
391-411
-
32
Sunderland T, Molchan S E, Little J T, Bahro M, Putnam K T, Weingartner H.
Pharmacologic
challenges in Alzheimer disease and normal controls: Cognitive modeling in
humans.
Alzheimer Disease and Associated
Disorders.
1997;
11
(Suppl)
S23-S26
-
33 Van
Dongen M. Efficacy of Ginkgo biloba in dementia and
cognitive decline. Proefschrift aan de Universiteit
Maastricht 1999: 1-192
-
34
Volz H -P, Gleiter C H.
Monoamine
oxidase inhibitors. A perspective on their use in the elderly.
Drugs
&
Aging.
1998;
13
341-355
-
35 Weiner M F, Schneider L S, Gray K F, Stern R G. Pharmacological
Management and Treatment of Dementia and Secondary Symptoms. In: Weiner MF (ed.): The Dementias - Diagnosis,
Management, and Research. American Psychiatric Press, Washington,
DC, London, Second
Edition 1996: 175-210
Anhang
Einige
Substanzklassen zur Behandlung der Alzheimer-Krankheit
(Azetylcholinesterase-Hemmer) und nicht näher spezifizierter Demenzformen
beziehungsweise Hirnleistungsstörungen im Alter
(Nootropika)
Azetylcholinesterase-Hemmer
Donepezil (Aricept®)
Rivastigmin (Exelon®)
Tacrin (Cognex®)
Nootropika
Dihydroergotoxin (z. B.
Hydergin®)
Ginkgo
biloba (z. B. Rökan®,
Tebonin®)
Nicergolin (z. B.
Sermion®)
Piracetam (Normabrain®,
Nootrop®)
Pyritinol (z. B.
Encephabol®)
Korrespondenz
Dr. med. Jindrich Strnad
Service
Universitaire de Psychogériatrie
Centre
Hospitalier Universitaire Vaudois
CH-1011 Lausanne
Telefon: 0041/21/3141119
Fax: 0041/21/3141110
eMail: Jindrich.Strnad@inst.hospvd.ch
